Mitotane had a minimum inhibitory concentration of 4 mg/L against A. baumannii FADDI-AB065 in broth microdilution testing. In NCI-H295R cells, Mitotane at 50 µM for 24 h increased lipid peroxidation by more than 7-fold compared with vehicle-treated controls. In a renal cancer cell study involving 786-O cells treated at 30 μM for 3 days, Mitotane significantly decreased proliferation and expression of HOXC5, ISL1, and VENTX. In polymyxin-resistant A. baumannii FADDI-AB225, Mitotane at 4 mg/L significantly reduced the polymyxin B MIC to 32-fold lower than baseline after 24-h exposure. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Minimum inhibitory concentration in A. baumannii
Cell-based study · A. baumannii FADDI-AB065 [1]
Mitotane had a minimum inhibitory concentration of 4 mg/L against A. baumannii FADDI-AB065, measured by broth microdilution.
Literature-Reported Treatment Conditions
- Exposure duration
- 37°C for 20 h
- Method
- broth microdilution
- Vehicle
- 2.5% DMSO (v/v)
- Reported limits
- Not stated in the sentences used: dose, control.
Methods and source locations
Compound reported in the paper: Mitotane
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Bacterial Isolates (S4); Materials and Methods > Antimicrobial Agents and Susceptibility Testing (S12, S16, S17); Table 1 (T1.h1, T1.h2, T1.r4)
minimum inhibitory concentrations (MICs): minimum inhibitory concentrations (MICs) — Materials and Methods > Antimicrobial Agents and Susceptibility Testing (S12); Table 1 (T1.h1, T1.h2, T1.r4)
Lipid peroxidation in adrenocortical cells
Cell-based study · NCI-H295R cells [2]
In NCI-H295R cells, Mitotane treatment at 50 µM for 24 h increased lipid peroxidation by more than 7-fold compared with vehicle-treated controls.
Literature-Reported Treatment Conditions
- Treatment concentration
- 25 µM; 50 µM
- Exposure duration
- 24 h
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: Mitotane
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Mitotane induces oxidation of lipids but not ferroptosis in adrenocortical cells (S45); Materials and methods > Cell culture (S60); Materials and methods > Lipid peroxidation assay (S75, S76); Fig. 4 legend (S111, S114)
Lipid peroxidation by BODIPY 581/591 C11: Lipid peroxidation by BODIPY 581/591 C11; comparator: control (=vehicle-) treated cells — Results > Mitotane induces oxidation of lipids but not ferroptosis in adrenocortical cells (S45); Fig. 4 legend (S111)
Proliferation and gene expression in renal cancer cells
Cell-based study · 786-O [3]
In a renal cancer cell study, 786-O cells were treated with Mitotane at 30 μM for 3 days. Treatment significantly decreased tumor cell proliferation and expression levels of HOXC5, ISL1, and VENTX.
Literature-Reported Treatment Conditions
- Treatment concentration
- 30 μM
- Exposure duration
- for 3 days
- Method
- cells were treated with
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Mitotane
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Tumor-specific regulatory elements in ccRCC (S56, S62); Materials and methods > Drug treatment (S302, S303)
The mRNA levels of VENTX: The mRNA levels of VENTX; comparator: DMSO — Results > Tumor-specific regulatory elements in ccRCC (S56, S62)
Polymyxin susceptibility in resistant A. baumannii
Cell-based study · polymyxin-resistant A. baumannii FADDI-AB225 [1]
In polymyxin-resistant A. baumannii FADDI-AB225, exposure to Mitotane at 4 mg/L resulted in a significantly reduced polymyxin B MIC, 32-fold lower than baseline after 24-h exposure.
Literature-Reported Treatment Conditions
- Treatment concentration
- 4 mg/L
- Exposure duration
- 24-h exposure
- Method
- added to achieve final concentrations
- Vehicle
- 0.4% DMSO (v/v)
Methods and source locations
Compound reported in the paper: Mitotane
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Time-Kill Studies (S26, S27); Results > MICs of Polymyxin B and Mitotane Against Polymyxin-Susceptible and -Resistant Isolates of A. baumannii, P. aeruginosa, and K. pneumoniae (S69, S70)
polymyxin B MIC: polymyxin B MIC; comparator: baseline — Results > MICs of Polymyxin B and Mitotane Against Polymyxin-Susceptible and -Resistant Isolates of A. baumannii, P. aeruginosa, and K. pneumoniae (S70)
